Johnson & Johnson's Q3 profits exceeded expectations, making progress in talcum powder litigation.
Johnson & Johnson released its third-quarter financial report on Tuesday, stating that driven by the soaring sales of the cancer drug Darzalex, Q3 profits exceeded expectations, while lowering the full-year outlook to account for a medical devices acquisition trade.
Morgan Stanley Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Raises Target Price to $175
Goldman Sachs Lowers Price Target on Johnson & Johnson to $159 From $162
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Johnson & Johnson's 'Better-Than-Expected Operational Execution' Drove Q3 Beat, RBC Says
Least Shorted S&P 500 Stocks in September